These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 616222)

  • 1. Plasma renin activity and angiotensin II during oral contraception.
    Soveri P; Fyhrquist F
    Ann Clin Res; 1977 Dec; 9(6):346-9. PubMed ID: 616222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin.
    Liukko P; Erkkola R; Lammintausta R
    Ann Chir Gynaecol; 1979; 68(5-6):155-9. PubMed ID: 161858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of oral contraceptives on plasma renin activity and plasma renin substrate concentration (author's transl)].
    Kaulhausen H; Oehm W; Fritzsche G; Breuer H
    Z Klin Chem Klin Biochem; 1974 Sep; 12(9):408-14. PubMed ID: 4372825
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes of plasma renin activity and angiotensin II levels in women with polycystic ovary syndrome].
    Li X; Shen H; Ge X
    Zhonghua Fu Chan Ke Za Zhi; 2000 Oct; 35(10):586-7. PubMed ID: 11372405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma renin activity, blood pressure and body weight during two years' oral contraception with two different low-estrogen combinations.
    Liukko P; Erkkola R; Grönroos M; Lammintausta R
    Ann Chir Gynaecol Suppl; 1987; 202():50-3. PubMed ID: 3310827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of plasma renin activity in Indian women using low estrogen combination pill as contraceptive [abstract].
    Gupta KC; Suhramaniam M; Jarag PD; Satoskar RS
    Indian J Pharmacol; 1982; 14(1):83-4. PubMed ID: 12266190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
    Elkik F; Basdevant A; Corvol P
    Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral contraceptive therapy on the renin-angiotensin system in normotensive and hypertensive women.
    Tapia HR; Johnson CE; Strong CG
    Obstet Gynecol; 1973 May; 41(5):643-9. PubMed ID: 4348864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma prolactin concentrations in women treated with low dose combination type oral contraceptives and in women using a d-norgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki P
    Ann Clin Res; 1978 Aug; 10(4):242-5. PubMed ID: 707973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral contraceptives and blood platelets].
    Davenas E; Ciavatti M; Poitevin B; Aubin M
    Homeopath Fr; 1985; 73(5):299-305. PubMed ID: 12281246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
    Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
    J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a low-dose oral contraceptive preparation: report of a study.
    Koetsawang S; Srisupandit S; Srivanaboon S; Bhiraleus P; Rajawatana D; Kiriwat O
    Mod Med Asia; 1975 Oct; 11(10):8-11. PubMed ID: 12279249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral contraceptives on the renin-angiotensin system and on blood pressure of normal young women.
    Beckerhoff R; Luetscher JA; Beckerhoff I; Nokes GW
    Johns Hopkins Med J; 1973 Feb; 132(2):80-7. PubMed ID: 4346163
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of a combined oral contraceptive on lactation and growth of the infant].
    Peralta O; Díaz S; Juez G; Herreros C; Casado ME; Salvatierra AM; Miranda P; Croxatto H
    Rev Chil Obstet Ginecol; 1983; 48(5):372-80. PubMed ID: 6681210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.